Shuttle Pharma Sets Sept 3 Vote on 17.6M Share Issuance, 8M Equity Plan Increase, and Name Change to United Compute
SHPH sits 78% above its 52-week low of $2.576.
Summary
Shuttle Pharmaceuticals filed its definitive proxy for a September 3 special meeting to approve issuance of up to 17.6 million shares tied to the United Dogecoin merger, an 8 million share increase to its equity incentive plan, and a name change to United Compute Inc.
Key Events · Corporate Governance and Compliance · SHPH
-
Special Meeting Set for Sept 3
Definitive proxy filed August 13, 2026 sets a special meeting for September 3, 2026, with a record date of August 5, 2026, to vote on five proposals.
-
17.6M Share Issuance Vote
Proposals 1 and 2 seek approval for issuance of up to approximately 17.6 million shares of common stock in connection with the United Dogecoin merger and related PIPE financing, including conversion of Series B-1 and B-2 preferred stock and exercise of pre-funded warrants.
-
Equity Plan Increase to 8.8M Shares
Proposal 3 seeks to increase the 2018 Equity Incentive Plan share reserve from 800,000 to 8,800,000 shares — an 8,000,000 share increase, representing a tenfold expansion of the plan.
-
Name Change to United Compute Inc.
Proposal 4 seeks approval to change the company's name from Shuttle Pharmaceuticals Holdings, Inc. to United Compute Inc., reflecting the pivot to digital infrastructure and Dogecoin mining.
Analysis · SHPH · Life Sciences
The definitive proxy finalizes the shareholder vote on the United Dogecoin merger-related share issuance, adding a new 8,000,000 share equity incentive plan increase and a corporate name change to United Compute Inc. The equity plan increase alone represents a massive expansion of the share reserve — from 800,000 to 8,800,000 shares — which, combined with the merger-related issuances, would significantly dilute existing holders. The special meeting is set for September 3, 2026, with a record date of August 5, 2026.
At the time of this filing, SHPH was trading at $4.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $2.58 to $55.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.